Forbes, Oct. 19, 2006
By: Josh Wolfe, Forbes/Wolfe Nanotech Report
It is clear that 2006 will not go down as a banner year for nanotech stocks. However, the real science of nanotechnology is making significant progress, which we report on regularly in the Forbes/Wolfe Nanotech Report. I can assure you that patient investors will be rewarded in nanotech and nano-related stocks.
Still, whenever I attend an investor conference, I am bombarded with questions about nanotechnology stocks not found in our core portfolio. Many of these are thinly traded over-the-counter stocks but are popular among speculators and traders. Several years ago, we featured a piece called “Nano Speculator’s Scorecard” that discussed the merits of some of these high flyers. My team and I have recently updated the Nano Speculator’s Scorecard.
Now, as then, inclusion on our Scorecard does not represent a recommendation by Forbes/Wolfe Nanotech Report. In fact, a quick glance at the Scorecard reveals that virtually every stock is nearer the bottom than the top of its 52-week range. More than a few of them are scraping the low end of their 52-week range, like Acacia Research-CombiMatrix (nasdaq: CMBX – news – people ), Advance Nanotech (otcbb: AVNA – news – people ), Biophan (otcbb: BIPH – news – people ), JMAR Technologies (nasdaq: JMAR – news – people ) and NaturalNano (otcbb: NNAN – news – people ).
There are some exceptions, like Canadian penny stock Raymor Resources–up almost 100% over this time last year, when it started under a dollar. The company’s second-quarter revenues were $505,827–its largest quarterly revenue to date, and an increase of 26% over the previous quarter. Notably, most of that action arose out of sales from the company’s metallic powders and thermal spray coating operations, rather than its single-walled carbon nanotube and nanomaterials business. However, the company is negotiating nanomaterials supply contracts with major aerospace, defense and high-tech companies that could generate extra revenue before the year is out.
Continue Article
[ return to table of contents ]